In a report published Thursday, Barrington Research analyst Michael Petusky assumed coverage on Haemonetics Corporation HAE with an Outperform rating and $46.00 price target.
In the report, Barrington Research noted, “Our price target is $46 and we arrive at our target by attaching a 11x multiple to our 2016 adjusted EBITDA estimate of $245.0 million and a 10.3x multiple to our 2017 adjusted EBITDA estimate of $262.7.0 million. We feel a 10-12x multiple range is appropriate for companies like Haemonetics whose businesses contains elements of both a devices company, as well as a healthcare services business.”
Haemonetics closed on Wednesday at $36.41.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in